Study Links Semaglutide to Increased Risk of Severe Eye Condition

New research suggests a significant association between the diabetes and weight loss drug and nonarteritic anterior ischemic optic neuropathy (NAION).

Patients with diabetes on semaglutide are over four times more likely to develop NAION.
Overweight patients on semaglutide face a sevenfold increased risk of NAION.
NAION is a rare but serious condition that can lead to permanent vision loss.
The study analyzed records from over 17,000 patients over six years.
Further research is needed to confirm these findings and understand the underlying mechanisms.